Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.

Renhowe, Paul and Pecchi, Sabina and Shafer, Cynthia and Machajewski, Timothy and Jazan, Elisa M and Taylor, Clarke and Antonios-Mccrea, William Jr. and Mcbride, Christopher and Frazier, Kelly and Wiesmann, Marion and Lapointe, Gena and Feucht, Paul and Warne, Robert and Heise, Carla C and Menezes, Daniel and Aardalen, Kimberly and Ye, Helen and He, Molly and Le, Vincent and Vora, Jayesh and Jansen, Johanna and Wernette-Hammond, Mary Ellen and Harris, Alex (2009) Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. Journal of Medicinal Chemistry, 52 (2). pp. 278-292. ISSN 1520-4804

Abstract

The inhibition of key receptor tyrosine kinases (RTKs) that are implicated in tumor vasculature formation and maintenance, as well as tumor progression and metastasis, has been a major focus in oncology research over the last several years. Many potent small molecule inhibitors of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) kinases have been evaluated. More recently, compounds that act through the complex inhibition of multiple kinase targets have been reported and may exhibit improved clinical efficacy. We report herein a series of potent, orally efficacious 4-amino-3-benzimidazol-2-ylhydroquinolin-2-one analogues as inhibitors of VEGF, PDGF, and fibroblast growth factor (FGF) receptor tyrosine kinases. Compounds in this class, such as 5 (TKI258), are reversible ATP-competitive inhibitors of VEGFR-2, FGFR-1, and PDGFRbeta with IC(50) values <0.1 microM. On the basis of its favorable in vitro and in vivo properties, compound 5 was selected for clinical evaluation and is currently in phase I clinical trials.

Item Type: Article
Related URLs:
Additional Information: archiving not formally supported by this publisher
Related URLs:
Date Deposited: 14 Dec 2009 13:48
Last Modified: 31 Jan 2013 00:53
URI: https://oak.novartis.com/id/eprint/1498

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.